Pharmacetuticals

The giant retailer shipped billions of opioid pills to pharmacies nationwide. An NPR investigation found employees warned company executives their stores were being used by "pill mill" doctors.

Thousands of lawsuits that ground to a halt because of COVID-19 are moving forward again as local, state and federal courts reopen around the U.S.

The first gene therapy for hemophilia could be approved by the FDA within six months, according to the drugmaker, raising hopes among families. But the drug's price could be $3 million per patient.

Drugs to treat multiple sclerosis can run $70,000 a year or more. Patients hoped competition from a generic version of one of the most popular brands would spur relief, but prices went up. Here's why.

As congressional lawmakers continue to turn up the heat on drugmakers, insurers and middlemen over the price of many medicines, one player says it will limit patients' share of the cost of insulin.

The Trump administration wants to increase transparency in prescription drug pricing. But health economists say the administration's call to tie prices to what other nations pay might work better.

Biologic drugs, often made with the help of living organisms, are especially lucrative because they have scant competition from biosimilars, drugs akin to generics. It's a different story in Europe.

A new book explores why getting a properly formulated medicine is hit-or-miss in much of the developing world — and why the issue is massively underreported.

The 39-page drug price plan includes an array of ideas that the administration will consider, but it's unclear which ones will be implemented.

Indian drugmakers like to come up with combos — two meds in one pill. They can make more money that way. And they say it's easier for patients to take one pill than two. But is there a downside?

A federal drug program blocks rural hospitals from getting discounts on rare-disease drugs, forcing staff to cut back on supplies of lifesaving medicines.